Literature DB >> 11564981

The action of salt and captopril on blood pressure in mice with genetic hypertension.

B J Leckie1.   

Abstract

OBJECTIVE: Does captopril lower blood pressure in genetically hypertensive, normotensive and hypotensive mice under normal and salt-loaded conditions? DESIGN AND METHODS: Groups of inbred mice that were genetically hypertensive, normotensive or hypotensive were given one of the following treatments: (a) captopril in drinking water for 7 days; controls were given water. (b) 0.85% saline to drink for up to 14 days; controls were given water. (c) Water or saline followed by captopril/water or captopril/saline for 7 days. (d) In hypotensive mice only, 0.85% saline, 0.85% saline plus captopril, water or captopril in water. Systolic blood pressures (SBP) were measured by a computerized tail-cuff sphygmomanometer. Results were compared by analysis of variance (ANOVA).
RESULTS: Captopril lowered SBP in all strains of mice. When saline was given with captopril, the fall in SBP was slower but the final SBP level was similar to that of mice given captopril in water. Hypotensive mice showed a transient rise in SBP on saline, which was abolished by concurrent treatment with captopril.
CONCLUSION: Captopril lowers blood pressure in hypertensive, normotensive and hypotensive mice. Salt-loading retards the captopril-induced fall in SBP, but the final level of SBP achieved is similar to that in mice given captopril with water. The BPL1 strain of mouse was slightly salt-sensitive, and this was abolished by captopril.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564981     DOI: 10.1097/00004872-200109000-00013

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

1.  An activated renin-angiotensin system maintains normal blood pressure in aryl hydrocarbon receptor heterozygous mice but not in null mice.

Authors:  Nan Zhang; Larry N Agbor; Jason A Scott; Tyler Zalobowski; Khalid M Elased; Alicia Trujillo; Melissa Skelton Duke; Valerie Wolf; Mary T Walsh; Jerry L Born; Linda A Felton; Jian Wang; Wei Wang; Nancy L Kanagy; Mary K Walker
Journal:  Biochem Pharmacol       Date:  2010-03-30       Impact factor: 5.858

2.  Regulatable atrial natriuretic peptide gene therapy for hypertension.

Authors:  Kurt J Schillinger; Sophia Y Tsai; George E Taffet; Anilkumar K Reddy; Ali J Marian; Mark L Entman; Kazuhiro Oka; Lawrence Chan; Bert W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-14       Impact factor: 11.205

Review 3.  Mechanisms Responsible for Genetic Hypertension in Schlager BPH/2 Mice.

Authors:  Kristy L Jackson; Geoffrey A Head; Cindy Gueguen; Emily R Stevenson; Kyungjoon Lim; Francine Z Marques
Journal:  Front Physiol       Date:  2019-10-18       Impact factor: 4.566

4.  Mechanical activation of the angiotensin II type 1 receptor contributes to abdominal aortic aneurysm formation.

Authors:  SarahRose Hall; Nicholas D Ward; Raj Patel; Armaan Amin-Javaheri; Hayes Lanford; R Tyler Grespin; Christine Couch; Ying Xiong; Rupak Mukherjee; Jeffrey A Jones; Jean Marie Ruddy
Journal:  JVS Vasc Sci       Date:  2021-07-24

5.  Soluble (pro)renin receptor induces endothelial dysfunction and hypertension in mice with diet-induced obesity via activation of angiotensin II type 1 receptor.

Authors:  Ziwei Fu; Fei Wang; Xiyang Liu; Jiajia Hu; Jiahui Su; Xiaohan Lu; Aihua Lu; Jae Min Cho; J David Symons; Chang-Jiang Zou; Tianxin Yang
Journal:  Clin Sci (Lond)       Date:  2021-03-26       Impact factor: 6.876

6.  Circadian Differences in the Contribution of the Brain Renin-Angiotensin System in Genetically Hypertensive Mice.

Authors:  Kristy L Jackson; Francine Z Marques; Kyungjoon Lim; Pamela J Davern; Geoffrey A Head
Journal:  Front Physiol       Date:  2018-03-19       Impact factor: 4.566

7.  Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.

Authors:  Masayo Koide; Osama F Harraz; Fabrice Dabertrand; Thomas A Longden; Hannah R Ferris; George C Wellman; David C Hill-Eubanks; Adam S Greenstein; Mark T Nelson
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.